457
Views
2
CrossRef citations to date
0
Altmetric
Letter

A unique combination of inhibitory and partially activating mutations in β3 of a patient with variant-type Glanzmann thrombasthenia

, , , , , , , , & show all
Pages 498-500 | Received 11 Mar 2010, Accepted 11 Mar 2010, Published online: 04 May 2010

Figures & data

Figure 1. Mutation screening by HRM analysis and direct sequencing of PCR-amplified products. Results are shown for ITGB3 exons 5 and 11 for family members of pat 1. In panels A and B, we illustrate normalized and temperature-shifted melting curves of mutated and control PCR amplicons (Roche Light cycler 480 ResoLight Dye; Roche Diagnostics, Meylan, France) (c.685C > T, Leu196Pro; and c.1871G > A, Cys598Tyr). Control patterns (pink) mutated patterns (red) are clearly distinguished. Whereas the ITGB3 exon 5 substitution was present in all of the family members (see superimposed lines), the propositus was the only family member to possess the exon 11 mutation. In panels C and D are shown the sequencing profiles of respective heterozygous mutated PCR products. Methodological details will be supplied on request.

Figure 1. Mutation screening by HRM analysis and direct sequencing of PCR-amplified products. Results are shown for ITGB3 exons 5 and 11 for family members of pat 1. In panels A and B, we illustrate normalized and temperature-shifted melting curves of mutated and control PCR amplicons (Roche Light cycler 480 ResoLight Dye; Roche Diagnostics, Meylan, France) (c.685C > T, Leu196Pro; and c.1871G > A, Cys598Tyr). Control patterns (pink) mutated patterns (red) are clearly distinguished. Whereas the ITGB3 exon 5 substitution was present in all of the family members (see superimposed lines), the propositus was the only family member to possess the exon 11 mutation. In panels C and D are shown the sequencing profiles of respective heterozygous mutated PCR products. Methodological details will be supplied on request.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.